Santhera's Raxone slows loss of respiratory function in real-world DMD study

Santhera said long-term treatment with Raxone idebenone reduced the annual rate of decline in percent predicted forced vital capacity (FVC)

Read the full 205 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE